 Edwin Asturias
Concepts (442)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Guatemala | 49 | 2023 | 267 | 4.050 |
Why?
| | Microcephaly | 4 | 2023 | 50 | 2.730 |
Why?
| | Vaccines | 6 | 2023 | 375 | 2.410 |
Why?
| | Poliovirus Vaccine, Inactivated | 6 | 2018 | 22 | 2.260 |
Why?
| | Rural Population | 14 | 2022 | 443 | 2.240 |
Why?
| | Influenza, Human | 6 | 2022 | 543 | 2.240 |
Why?
| | Zika Virus Infection | 5 | 2022 | 85 | 2.160 |
Why?
| | Poliomyelitis | 8 | 2018 | 27 | 2.030 |
Why?
| | Vaccination | 14 | 2023 | 1202 | 2.010 |
Why?
| | Poliovirus Vaccine, Oral | 7 | 2018 | 19 | 1.870 |
Why?
| | Zika Virus | 4 | 2022 | 61 | 1.690 |
Why?
| | Infant | 38 | 2023 | 7944 | 1.600 |
Why?
| | Child Development | 3 | 2022 | 384 | 1.290 |
Why?
| | Viral Vaccines | 3 | 2018 | 88 | 1.250 |
Why?
| | Caliciviridae Infections | 2 | 2018 | 17 | 1.160 |
Why?
| | Norovirus | 2 | 2018 | 23 | 1.150 |
Why?
| | Poliovirus | 6 | 2018 | 77 | 1.130 |
Why?
| | Virus Shedding | 8 | 2017 | 39 | 1.110 |
Why?
| | Haemophilus Vaccines | 5 | 2016 | 27 | 1.080 |
Why?
| | Gastroenteritis | 2 | 2017 | 65 | 1.080 |
Why?
| | Reminder Systems | 2 | 2019 | 159 | 1.030 |
Why?
| | Text Messaging | 2 | 2019 | 152 | 0.990 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2023 | 1168 | 0.990 |
Why?
| | Growth Disorders | 2 | 2023 | 77 | 0.980 |
Why?
| | Hepatitis B Vaccines | 4 | 2016 | 46 | 0.950 |
Why?
| | Fever | 2 | 2017 | 280 | 0.940 |
Why?
| | Immunization Schedule | 5 | 2017 | 183 | 0.900 |
Why?
| | Streptococcal Vaccines | 1 | 2023 | 6 | 0.880 |
Why?
| | Child, Preschool | 23 | 2022 | 9115 | 0.870 |
Why?
| | Humans | 87 | 2024 | 114049 | 0.870 |
Why?
| | Immunization | 4 | 2023 | 397 | 0.840 |
Why?
| | Dengue Virus | 5 | 2022 | 31 | 0.840 |
Why?
| | Meningitis, Meningococcal | 1 | 2022 | 5 | 0.830 |
Why?
| | Neisseria meningitidis | 1 | 2022 | 18 | 0.820 |
Why?
| | Meningococcal Infections | 1 | 2022 | 20 | 0.820 |
Why?
| | Cell Phone | 3 | 2019 | 76 | 0.820 |
Why?
| | Meningococcal Vaccines | 1 | 2022 | 48 | 0.790 |
Why?
| | Dengue | 5 | 2022 | 59 | 0.790 |
Why?
| | Child | 22 | 2023 | 18404 | 0.770 |
Why?
| | Streptococcal Infections | 1 | 2023 | 127 | 0.760 |
Why?
| | Antibodies, Neutralizing | 4 | 2017 | 222 | 0.740 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2022 | 285 | 0.720 |
Why?
| | Rural Health Services | 2 | 2019 | 92 | 0.700 |
Why?
| | Virus Diseases | 1 | 2022 | 195 | 0.700 |
Why?
| | Endpoint Determination | 1 | 2020 | 68 | 0.690 |
Why?
| | Diarrhea | 5 | 2023 | 170 | 0.660 |
Why?
| | Contraception | 4 | 2022 | 117 | 0.660 |
Why?
| | Influenza Vaccines | 3 | 2021 | 497 | 0.660 |
Why?
| | Immunity, Humoral | 3 | 2017 | 112 | 0.650 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2016 | 25 | 0.650 |
Why?
| | Female | 48 | 2024 | 59326 | 0.640 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 675 | 0.640 |
Why?
| | Prospective Studies | 13 | 2023 | 6195 | 0.630 |
Why?
| | Adolescent Health | 1 | 2019 | 37 | 0.620 |
Why?
| | Immunity, Mucosal | 2 | 2016 | 84 | 0.620 |
Why?
| | Arbovirus Infections | 1 | 2018 | 17 | 0.620 |
Why?
| | Community Health Services | 2 | 2019 | 212 | 0.610 |
Why?
| | Sentinel Surveillance | 2 | 2017 | 38 | 0.600 |
Why?
| | Haemophilus influenzae type b | 2 | 2014 | 10 | 0.600 |
Why?
| | Infant, Newborn | 13 | 2022 | 5038 | 0.580 |
Why?
| | Carrier State | 3 | 2014 | 54 | 0.580 |
Why?
| | Urban Health Services | 1 | 2017 | 60 | 0.560 |
Why?
| | Immunogenicity, Vaccine | 1 | 2017 | 25 | 0.560 |
Why?
| | Physician Assistants | 1 | 2017 | 65 | 0.530 |
Why?
| | Consumer Product Safety | 1 | 2016 | 30 | 0.530 |
Why?
| | Parents | 3 | 2023 | 1181 | 0.530 |
Why?
| | Neonatal Screening | 1 | 2017 | 151 | 0.520 |
Why?
| | Community Health Planning | 1 | 2016 | 42 | 0.520 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 43 | 0.520 |
Why?
| | Family Planning Services | 3 | 2022 | 68 | 0.510 |
Why?
| | Schools | 1 | 2019 | 396 | 0.510 |
Why?
| | Population Health | 1 | 2016 | 42 | 0.500 |
Why?
| | Mobile Applications | 1 | 2017 | 140 | 0.500 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 18 | 0.500 |
Why?
| | Latin America | 5 | 2018 | 68 | 0.490 |
Why?
| | Male | 37 | 2024 | 55398 | 0.490 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2014 | 6 | 0.480 |
Why?
| | Sexual Behavior | 1 | 2019 | 434 | 0.480 |
Why?
| | Caregivers | 1 | 2021 | 713 | 0.480 |
Why?
| | Needs Assessment | 2 | 2016 | 315 | 0.480 |
Why?
| | Advisory Committees | 1 | 2016 | 207 | 0.480 |
Why?
| | Castleman Disease | 1 | 2014 | 12 | 0.470 |
Why?
| | Haemophilus Infections | 1 | 2014 | 28 | 0.470 |
Why?
| | Serogroup | 4 | 2018 | 27 | 0.470 |
Why?
| | Exanthema | 1 | 2015 | 74 | 0.470 |
Why?
| | Herpes Zoster | 2 | 2015 | 330 | 0.460 |
Why?
| | Population Surveillance | 1 | 2017 | 385 | 0.460 |
Why?
| | Brain Diseases | 1 | 2015 | 124 | 0.450 |
Why?
| | Adolescent Behavior | 1 | 2019 | 486 | 0.450 |
Why?
| | Global Health | 1 | 2016 | 287 | 0.450 |
Why?
| | Bacterial Capsules | 2 | 2014 | 28 | 0.440 |
Why?
| | Calcitonin | 1 | 2013 | 23 | 0.440 |
Why?
| | Receptors, Interleukin-6 | 1 | 2013 | 34 | 0.430 |
Why?
| | Health Behavior | 1 | 2019 | 701 | 0.430 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2013 | 63 | 0.430 |
Why?
| | Hospitalization | 7 | 2022 | 1762 | 0.420 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2013 | 68 | 0.420 |
Why?
| | Antibodies, Bacterial | 2 | 2014 | 119 | 0.410 |
Why?
| | Feces | 8 | 2018 | 372 | 0.410 |
Why?
| | Protein Precursors | 1 | 2013 | 119 | 0.410 |
Why?
| | Bacterial Infections | 2 | 2013 | 217 | 0.410 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 660 | 0.410 |
Why?
| | Pregnancy | 12 | 2022 | 5499 | 0.400 |
Why?
| | Diet | 1 | 2019 | 1080 | 0.380 |
Why?
| | Intestines | 4 | 2018 | 325 | 0.380 |
Why?
| | Intestinal Mucosa | 1 | 2016 | 532 | 0.370 |
Why?
| | Adolescent | 15 | 2019 | 17802 | 0.370 |
Why?
| | Surveys and Questionnaires | 5 | 2021 | 4595 | 0.350 |
Why?
| | Contraceptive Agents | 2 | 2021 | 54 | 0.350 |
Why?
| | Saccharum | 3 | 2020 | 59 | 0.340 |
Why?
| | Adult | 23 | 2024 | 30377 | 0.340 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 641 | 0.330 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 10 | 0.320 |
Why?
| | Antibodies, Viral | 7 | 2022 | 520 | 0.320 |
Why?
| | Young Adult | 11 | 2020 | 10446 | 0.310 |
Why?
| | Agriculture | 2 | 2020 | 71 | 0.310 |
Why?
| | Delivery, Obstetric | 2 | 2019 | 118 | 0.310 |
Why?
| | Multiplex Polymerase Chain Reaction | 2 | 2019 | 46 | 0.300 |
Why?
| | Dengue Vaccines | 2 | 2018 | 9 | 0.300 |
Why?
| | Malnutrition | 1 | 2009 | 62 | 0.300 |
Why?
| | Urban Population | 3 | 2019 | 396 | 0.300 |
Why?
| | Primary Health Care | 1 | 2017 | 1502 | 0.290 |
Why?
| | World Health Organization | 3 | 2017 | 101 | 0.290 |
Why?
| | Appointments and Schedules | 2 | 2019 | 70 | 0.290 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 4402 | 0.290 |
Why?
| | RNA, Viral | 2 | 2021 | 565 | 0.280 |
Why?
| | Family Characteristics | 2 | 2018 | 151 | 0.280 |
Why?
| | Acute Disease | 3 | 2019 | 908 | 0.270 |
Why?
| | Seroconversion | 2 | 2017 | 45 | 0.270 |
Why?
| | Glomerular Filtration Rate | 2 | 2020 | 605 | 0.260 |
Why?
| | Viruses | 2 | 2023 | 94 | 0.240 |
Why?
| | Viral Load | 2 | 2024 | 405 | 0.240 |
Why?
| | Streptococcus pneumoniae | 3 | 2016 | 133 | 0.240 |
Why?
| | Anthropometry | 2 | 2022 | 183 | 0.240 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 59 | 0.230 |
Why?
| | Postpartum Period | 3 | 2022 | 275 | 0.230 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.220 |
Why?
| | Culex | 1 | 2023 | 13 | 0.220 |
Why?
| | Cohort Studies | 4 | 2022 | 4883 | 0.220 |
Why?
| | Ritonavir | 1 | 2024 | 71 | 0.220 |
Why?
| | Streptococcus pyogenes | 1 | 2023 | 30 | 0.220 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2003 | 38 | 0.220 |
Why?
| | Biomarkers | 1 | 2013 | 3397 | 0.220 |
Why?
| | Incidence | 4 | 2022 | 2314 | 0.210 |
Why?
| | Psychometrics | 3 | 2021 | 608 | 0.210 |
Why?
| | Quality Improvement | 5 | 2022 | 944 | 0.210 |
Why?
| | Aedes | 1 | 2023 | 55 | 0.210 |
Why?
| | Propensity Score | 1 | 2024 | 225 | 0.210 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 219 | 0.210 |
Why?
| | Health Services Accessibility | 2 | 2020 | 756 | 0.210 |
Why?
| | Postnatal Care | 2 | 2021 | 65 | 0.210 |
Why?
| | Immunization Programs | 2 | 2016 | 204 | 0.210 |
Why?
| | Vomiting | 1 | 2023 | 122 | 0.200 |
Why?
| | Cough | 1 | 2023 | 107 | 0.200 |
Why?
| | Travel | 3 | 2015 | 121 | 0.200 |
Why?
| | Seroepidemiologic Studies | 2 | 2022 | 137 | 0.200 |
Why?
| | Vital Signs | 1 | 2022 | 37 | 0.200 |
Why?
| | Regression Analysis | 2 | 2022 | 945 | 0.200 |
Why?
| | Meningitis, Bacterial | 2 | 2015 | 48 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 949 | 0.190 |
Why?
| | Herpesvirus 3, Human | 2 | 2015 | 377 | 0.190 |
Why?
| | Escherichia coli Vaccines | 2 | 2013 | 3 | 0.190 |
Why?
| | Health Promotion | 2 | 2019 | 675 | 0.190 |
Why?
| | Attitude | 1 | 2023 | 228 | 0.190 |
Why?
| | Reproducibility of Results | 4 | 2021 | 2764 | 0.190 |
Why?
| | Cesarean Section | 2 | 2019 | 169 | 0.180 |
Why?
| | Midwifery | 1 | 2022 | 45 | 0.180 |
Why?
| | Outpatients | 1 | 2024 | 325 | 0.180 |
Why?
| | Malaria Vaccines | 1 | 2020 | 6 | 0.180 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2021 | 40 | 0.180 |
Why?
| | Emergency Service, Hospital | 2 | 2022 | 1815 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 239 | 0.180 |
Why?
| | Maternal Health Services | 1 | 2022 | 79 | 0.180 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2015 | 61 | 0.180 |
Why?
| | Birth Intervals | 1 | 2020 | 16 | 0.180 |
Why?
| | Yellow fever virus | 1 | 2020 | 3 | 0.180 |
Why?
| | Yellow Fever | 1 | 2020 | 7 | 0.170 |
Why?
| | Absenteeism | 1 | 2020 | 40 | 0.170 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 92 | 0.170 |
Why?
| | Cesarean Section, Repeat | 1 | 2019 | 9 | 0.170 |
Why?
| | Intensive Care, Neonatal | 1 | 2020 | 39 | 0.170 |
Why?
| | Vaccination Refusal | 1 | 2020 | 69 | 0.170 |
Why?
| | Agricultural Workers' Diseases | 1 | 2020 | 23 | 0.170 |
Why?
| | Contraception Behavior | 1 | 2020 | 80 | 0.170 |
Why?
| | Drug Discovery | 1 | 2020 | 123 | 0.170 |
Why?
| | Vaginal Birth after Cesarean | 1 | 2019 | 21 | 0.170 |
Why?
| | Language Tests | 1 | 2019 | 31 | 0.160 |
Why?
| | Language Development Disorders | 1 | 2019 | 38 | 0.160 |
Why?
| | Motor Skills | 1 | 2020 | 82 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 314 | 0.160 |
Why?
| | Maternal Age | 1 | 2019 | 116 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 926 | 0.160 |
Why?
| | Arboviruses | 1 | 2018 | 10 | 0.160 |
Why?
| | Seasons | 1 | 2021 | 440 | 0.160 |
Why?
| | Heat Stress Disorders | 1 | 2019 | 40 | 0.160 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 139 | 0.160 |
Why?
| | Neoplasms | 2 | 2016 | 2086 | 0.150 |
Why?
| | Farmers | 1 | 2019 | 42 | 0.150 |
Why?
| | Thinness | 1 | 2019 | 87 | 0.150 |
Why?
| | Puerto Rico | 1 | 2018 | 51 | 0.150 |
Why?
| | Entamoeba histolytica | 1 | 2018 | 7 | 0.150 |
Why?
| | Mothers | 3 | 2022 | 650 | 0.150 |
Why?
| | Pregnancy in Adolescence | 1 | 2019 | 79 | 0.150 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2020 | 176 | 0.150 |
Why?
| | Vulnerable Populations | 1 | 2019 | 129 | 0.150 |
Why?
| | Chikungunya Fever | 1 | 2018 | 61 | 0.150 |
Why?
| | Pregnant Women | 1 | 2019 | 129 | 0.150 |
Why?
| | Treatment Refusal | 1 | 2018 | 85 | 0.150 |
Why?
| | Occupational Health | 2 | 2018 | 165 | 0.140 |
Why?
| | HIV Infections | 2 | 2014 | 2453 | 0.140 |
Why?
| | Educational Status | 1 | 2019 | 408 | 0.140 |
Why?
| | Child Health | 1 | 2019 | 126 | 0.140 |
Why?
| | Public Health | 2 | 2018 | 433 | 0.140 |
Why?
| | Databases, Factual | 3 | 2019 | 1125 | 0.140 |
Why?
| | Vaccines, Attenuated | 1 | 2017 | 113 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 87 | 0.140 |
Why?
| | Health Surveys | 1 | 2019 | 441 | 0.140 |
Why?
| | Pneumococcal Infections | 2 | 2016 | 91 | 0.140 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 63 | 0.140 |
Why?
| | Poliovirus Vaccines | 1 | 2016 | 3 | 0.140 |
Why?
| | Child Behavior | 1 | 2019 | 220 | 0.140 |
Why?
| | Myelitis | 1 | 2018 | 88 | 0.140 |
Why?
| | Antigens, Viral | 1 | 2017 | 176 | 0.140 |
Why?
| | Risk Factors | 7 | 2020 | 8614 | 0.140 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 89 | 0.130 |
Why?
| | Panama | 1 | 2016 | 9 | 0.130 |
Why?
| | Dominican Republic | 1 | 2016 | 18 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 295 | 0.130 |
Why?
| | Colombia | 1 | 2016 | 34 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2019 | 255 | 0.130 |
Why?
| | Vaccines, Combined | 2 | 2013 | 46 | 0.130 |
Why?
| | Learning | 1 | 2020 | 346 | 0.130 |
Why?
| | Community Health Nursing | 1 | 2016 | 57 | 0.130 |
Why?
| | Risk-Taking | 1 | 2019 | 333 | 0.130 |
Why?
| | Peru | 1 | 2016 | 54 | 0.130 |
Why?
| | Sanitation | 1 | 2016 | 49 | 0.130 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2016 | 41 | 0.130 |
Why?
| | Water Supply | 1 | 2016 | 67 | 0.130 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2015 | 11 | 0.130 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 48 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 241 | 0.130 |
Why?
| | Patient Preference | 1 | 2017 | 164 | 0.120 |
Why?
| | Single-Blind Method | 1 | 2016 | 259 | 0.120 |
Why?
| | Enterovirus Infections | 1 | 2018 | 160 | 0.120 |
Why?
| | Analysis of Variance | 1 | 2018 | 1218 | 0.120 |
Why?
| | Chickenpox | 1 | 2016 | 93 | 0.120 |
Why?
| | Disease Outbreaks | 1 | 2018 | 305 | 0.120 |
Why?
| | Community Participation | 1 | 2016 | 112 | 0.120 |
Why?
| | Typhoid Fever | 1 | 2015 | 9 | 0.120 |
Why?
| | Health Information Systems | 1 | 2015 | 16 | 0.120 |
Why?
| | Data Collection | 1 | 2018 | 618 | 0.120 |
Why?
| | Education, Nursing | 1 | 2016 | 78 | 0.120 |
Why?
| | Overweight | 1 | 2019 | 473 | 0.120 |
Why?
| | Biomedical Research | 1 | 2020 | 582 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2020 | 486 | 0.120 |
Why?
| | Antibody Affinity | 1 | 2014 | 51 | 0.120 |
Why?
| | Malaria | 1 | 2015 | 48 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2537 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2015 | 281 | 0.120 |
Why?
| | Vincristine | 1 | 2014 | 98 | 0.110 |
Why?
| | Pleural Effusion | 1 | 2014 | 46 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 82 | 0.110 |
Why?
| | Students | 1 | 2019 | 499 | 0.110 |
Why?
| | Colorado | 2 | 2020 | 4090 | 0.110 |
Why?
| | Cyclophosphamide | 1 | 2014 | 214 | 0.110 |
Why?
| | History, 21st Century | 1 | 2014 | 160 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2021 | 3003 | 0.110 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 76 | 0.110 |
Why?
| | Universities | 1 | 2016 | 338 | 0.110 |
Why?
| | Rituximab | 1 | 2014 | 148 | 0.110 |
Why?
| | Enterotoxins | 1 | 2013 | 88 | 0.110 |
Why?
| | Prednisone | 1 | 2014 | 229 | 0.110 |
Why?
| | History, 20th Century | 1 | 2014 | 265 | 0.110 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 31 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1080 | 0.110 |
Why?
| | Education, Medical | 1 | 2016 | 214 | 0.110 |
Why?
| | Doxorubicin | 1 | 2014 | 286 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2015 | 127 | 0.110 |
Why?
| | Bacterial Toxins | 1 | 2013 | 103 | 0.110 |
Why?
| | Causality | 1 | 2013 | 104 | 0.110 |
Why?
| | Health Policy | 1 | 2016 | 330 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2019 | 828 | 0.100 |
Why?
| | Lymphocytes | 1 | 2014 | 327 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1518 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1381 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 637 | 0.100 |
Why?
| | Aged, 80 and over | 1 | 2023 | 6307 | 0.100 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 162 | 0.100 |
Why?
| | Hypertension | 1 | 2020 | 1052 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2014 | 415 | 0.100 |
Why?
| | Program Evaluation | 1 | 2016 | 820 | 0.100 |
Why?
| | Kidney | 1 | 2018 | 1182 | 0.090 |
Why?
| | Clinical Competence | 1 | 2017 | 882 | 0.090 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 175 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2014 | 673 | 0.090 |
Why?
| | Escherichia coli | 1 | 2013 | 723 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 138 | 0.080 |
Why?
| | Immunization, Secondary | 1 | 2010 | 82 | 0.080 |
Why?
| | Physicians | 1 | 2017 | 765 | 0.080 |
Why?
| | Creatinine | 2 | 2020 | 424 | 0.070 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 38 | 0.070 |
Why?
| | Penicillins | 1 | 2007 | 52 | 0.070 |
Why?
| | Nasopharynx | 1 | 2007 | 61 | 0.070 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2007 | 61 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1356 | 0.070 |
Why?
| | Middle Aged | 5 | 2024 | 26607 | 0.070 |
Why?
| | Cities | 2 | 2016 | 80 | 0.060 |
Why?
| | Neuropsychological Tests | 2 | 2020 | 926 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2272 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 714 | 0.060 |
Why?
| | Sepsis | 2 | 2003 | 507 | 0.060 |
Why?
| | Mexico | 3 | 2013 | 162 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1690 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2020 | 9049 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2003 | 48 | 0.060 |
Why?
| | Mosquito Vectors | 1 | 2023 | 21 | 0.050 |
Why?
| | Antiviral Agents | 2 | 2024 | 642 | 0.050 |
Why?
| | Developing Countries | 2 | 2016 | 231 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1204 | 0.050 |
Why?
| | Chickens | 1 | 2023 | 180 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1311 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2384 | 0.050 |
Why?
| | Cross Reactions | 1 | 2022 | 118 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 241 | 0.050 |
Why?
| | Hospitals | 2 | 2016 | 581 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2013 | 117 | 0.050 |
Why?
| | Paraguay | 1 | 2020 | 3 | 0.040 |
Why?
| | Sri Lanka | 1 | 2020 | 7 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 787 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6077 | 0.040 |
Why?
| | Endemic Diseases | 1 | 2020 | 23 | 0.040 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 42 | 0.040 |
Why?
| | Translations | 1 | 2020 | 16 | 0.040 |
Why?
| | Home Health Nursing | 1 | 2019 | 9 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2015 | 478 | 0.040 |
Why?
| | Prenatal Care | 1 | 2022 | 250 | 0.040 |
Why?
| | Parity | 1 | 2019 | 97 | 0.040 |
Why?
| | Specific Gravity | 1 | 2019 | 11 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2022 | 735 | 0.040 |
Why?
| | Child Language | 1 | 2019 | 22 | 0.040 |
Why?
| | Translating | 1 | 2019 | 35 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2020 | 12521 | 0.040 |
Why?
| | Rural Health | 1 | 2019 | 67 | 0.040 |
Why?
| | Electrolytes | 1 | 2019 | 55 | 0.040 |
Why?
| | Reproductive Health | 1 | 2019 | 70 | 0.040 |
Why?
| | Dehydration | 1 | 2019 | 40 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 37 | 0.040 |
Why?
| | Bacteria | 2 | 2019 | 725 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 150 | 0.040 |
Why?
| | Culturally Competent Care | 1 | 2019 | 48 | 0.040 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 11 | 0.040 |
Why?
| | House Calls | 1 | 2019 | 115 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 120 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 337 | 0.040 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 115 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2019 | 492 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 206 | 0.040 |
Why?
| | Licensure | 1 | 2017 | 10 | 0.040 |
Why?
| | Choice Behavior | 1 | 2019 | 150 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 2017 | 80 | 0.040 |
Why?
| | Counseling | 1 | 2020 | 342 | 0.040 |
Why?
| | Epitope Mapping | 1 | 2017 | 51 | 0.040 |
Why?
| | Women's Health | 1 | 2019 | 270 | 0.040 |
Why?
| | Francisella | 1 | 1997 | 1 | 0.040 |
Why?
| | Parenteral Nutrition | 1 | 1998 | 96 | 0.040 |
Why?
| | Paralysis | 1 | 2018 | 66 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 169 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2013 | 1656 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1997 | 36 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2017 | 323 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1997 | 59 | 0.030 |
Why?
| | Enterovirus D, Human | 1 | 2018 | 72 | 0.030 |
Why?
| | ROC Curve | 1 | 2017 | 441 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2018 | 274 | 0.030 |
Why?
| | Acyclovir | 1 | 2016 | 100 | 0.030 |
Why?
| | Chile | 1 | 2015 | 16 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 341 | 0.030 |
Why?
| | Cholestasis | 1 | 1998 | 225 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 336 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 528 | 0.030 |
Why?
| | IgG Deficiency | 2 | 2006 | 8 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2016 | 370 | 0.030 |
Why?
| | IgA Deficiency | 2 | 2006 | 5 | 0.030 |
Why?
| | Spleen | 1 | 1997 | 485 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2016 | 131 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 191 | 0.030 |
Why?
| | Blood Pressure | 1 | 2021 | 1531 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 460 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 723 | 0.030 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 151 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 1981 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2247 | 0.030 |
Why?
| | Europe | 1 | 2013 | 332 | 0.030 |
Why?
| | Checklist | 1 | 2013 | 84 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 437 | 0.030 |
Why?
| | Survival Rate | 1 | 2016 | 1638 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 493 | 0.020 |
Why?
| | Survival Analysis | 1 | 2015 | 1206 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1036 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1447 | 0.020 |
Why?
| | Oncology Service, Hospital | 1 | 2011 | 15 | 0.020 |
Why?
| | Oseltamivir | 1 | 2011 | 11 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2015 | 591 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1257 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1382 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 295 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 1957 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 2011 | 1471 | 0.020 |
Why?
| | Animals | 2 | 2023 | 31565 | 0.020 |
Why?
| | El Salvador | 1 | 2010 | 5 | 0.020 |
Why?
| | Aged | 2 | 2024 | 18971 | 0.020 |
Why?
| | Latex Fixation Tests | 1 | 2008 | 3 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2015 | 1311 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2008 | 19 | 0.020 |
Why?
| | Coma | 1 | 2008 | 30 | 0.020 |
Why?
| | Leukocytosis | 1 | 2008 | 34 | 0.020 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 63 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2008 | 90 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 3861 | 0.020 |
Why?
| | Postoperative Complications | 1 | 1998 | 2122 | 0.020 |
Why?
| | Child Day Care Centers | 1 | 2007 | 33 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4392 | 0.020 |
Why?
| | Shock | 1 | 2008 | 83 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 2958 | 0.020 |
Why?
| | Bacteremia | 1 | 2008 | 160 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2007 | 300 | 0.020 |
Why?
| | Algorithms | 1 | 2013 | 1469 | 0.020 |
Why?
| | Ethiopia | 1 | 2006 | 31 | 0.020 |
Why?
| | Pakistan | 1 | 2006 | 69 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1875 | 0.020 |
Why?
| | United States | 2 | 2015 | 12137 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2007 | 479 | 0.010 |
Why?
| | Brazil | 1 | 2004 | 89 | 0.010 |
Why?
| | Common Variable Immunodeficiency | 1 | 2004 | 25 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 2004 | 30 | 0.010 |
Why?
| | United Kingdom | 1 | 2004 | 226 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 302 | 0.010 |
Why?
| | Short Bowel Syndrome | 1 | 1998 | 19 | 0.010 |
Why?
| | Bilirubin | 1 | 1998 | 88 | 0.010 |
Why?
| | Liver Failure | 1 | 1998 | 73 | 0.010 |
Why?
| | Water Microbiology | 1 | 1997 | 78 | 0.010 |
Why?
| | Abscess | 1 | 1997 | 70 | 0.010 |
Why?
|
|
Asturias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|